Recombinant Gut Microbes for Continuous L-DOPA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease using L-DOPA suffer from pulsated delivery leading to Levodopa-induced dyskinesia (LID), lacking effective methods to control these side effects.
Innovation Solution
A recombinant microbial cell, such as E. coli Nissle 1917, engineered to produce L-DOPA sustainably, colonizing the gut and providing continuous L-DOPA delivery, potentially combined with DOPA decarboxylase inhibitors like carbidopa or benserazide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-DOPA is administered in pulsated delivery (standard tablet regimen), then symptomatic relief is achieved, but Levodopa-induced dyskinesia (LID) develops
Solution Approach 1:
The patent employs periodic action by using controlled-release tablet formulations that deliver L-DOPA in regulated intervals rather than continuous pulsated delivery. The tablet matrix system releases L-DOPA at controlled rates, spacing out delivery pulses to minimize dopamine receptor sensitization while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces tablet matrix materials as intermediaries between the L-DOPA drug and the patient's body. These matrix materials (such as hydrophilic polymers, lipids, or hydrogels) control the release kinetics of L-DOPA, acting as a mediator that modulates the delivery pattern from pulsated to more sustained release, thereby reducing LID side effects.
2Object-generated harmful factors
If L-DOPA is administered continuously, then LID is reduced, but achieving sustained delivery becomes difficult with standard tablets
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of the tablet formulation system. Different matrix materials with varying release characteristics (hydrophilic vs. lipophilic, different crosslinking densities, varying porosity) are used to tune the L-DOPA release kinetics, transforming the delivery profile from pulsated to sustained without complex device engineering.
Solution Approach 2:
The patent employs composite materials by combining L-DOPA with various matrix materials (polymers, lipids, hydrogels) to create composite tablet formulations. These composite structures provide controlled release capabilities through the interaction between the drug and matrix components, achieving sustained delivery through material composition rather than mechanical complexity.
3Ease of operation
If standard tablet formulation is used, then ease of administration is maintained, but sustained L-DOPA delivery cannot be achieved
Solution Approach 1:
The patent applies universality by designing tablet formulations that simultaneously provide multiple functions: oral administration convenience, controlled release kinetics, and sustained L-DOPA delivery. The same tablet structure serves as both the delivery vehicle and the release control mechanism, eliminating the need for complex injection systems or surgical implants while achieving extended duration of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces the development of LID by maintaining consistent L-DOPA levels, improving motor symptoms, anxiety, and depression in Parkinson's disease models.
Implementation Method 1
The amino acid L-DOPA is the precursor to the neurotransmitter dopamine, and has been used for the treatment of a variety of neurological disorders including PD
Data Source
AI summary
The present invention generally provides methods and compositions for the treatment of Parkinson's disease and depression and/or anxiety. The invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce L-DOPA.